Kestra Medical Technologies (KMTS) Common Equity (2024 - 2026)

Kestra Medical Technologies (KMTS) has 3 years of Common Equity data on file, last reported at $288.0 million in Q1 2026.

• Common Equity for Q1 2026 came in at $288.0 million, up 211.67% year-over-year; the trailing twelve-month figure through Jan 2026 was $288.0 million (up 211.67% YoY), and the FY2025 annual result was $205.4 million, up 198.1% from the prior year.
• Common Equity improved to $288.0 million in Q1 2026 per KMTS's latest filing, from $164.1 million in the prior quarter.
• Over five years, Common Equity peaked at $288.0 million in Q1 2026 and troughed at -$257.9 million in Q1 2025.
• A 3-year average of $13.1 million and a median of $164.1 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2025 and 2026: Common Equity slumped 230.96% in 2025, then jumped 211.67% in 2026.
• A 3-year view of Common Equity shows it stood at -$236.5 million in 2024, then jumped by 169.37% to $164.1 million in 2025, then jumped by 75.52% to $288.0 million in 2026.
• Business Quant data shows KMTS's Common Equity at $288.0 million in Q1 2026, $164.1 million in Q4 2025, and $184.2 million in Q3 2025.